Contact CFFC


Clinical Trial Alerts – April 2019

Cystic Fibrosis Foundation distributed the following clinical trial update in April. Click the trial title to get more details.

April 1, 2019

Phase 3 study of lumacaftor/ivacaftor (Orkambi®) in babies with two copies of the F508del CFTR mutation (Part B)

Status: Enrolling

Description: This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.

Age: 1 Years to 2 Years

Mutation: Two Copies F508del

Fev1% Predicted: No FEV1 Limit

Number of Visits: 11

Length of Participation: 38 weeks link:

Comments are closed.